NAS:ARNA (USA) Also trade in: Germany UK

Arena Pharmaceuticals Inc

$ 53.5 0.3 (0.56%)
Volume: 170,804 Avg Vol (1m): 523,780
Market Cap $: 2.64 Bil Enterprise Value $: 1.59 Bil
P/E (TTM): 4.40 P/B: 2.21
Earnings Power Value -147.49
Net Current Asset Value 20.28
Tangible Book 24.26
Projected FCF 30.19
Median P/S Value 419.19
Graham Number 81.27
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 21.26
Cash-To-Debt ranked lower than
56.96% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ARNA: 21.26
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.46, Med: 4.45, Max: 11204.39
Current: 21.26
0.46
11204.39
Equity-to-Asset 0.94
Equity-to-Asset ranked higher than
83.36% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ARNA: 0.94
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.02, Med: 0.56, Max: 0.98
Current: 0.94
0.02
0.98
Debt-to-Equity 0.04
Debt-to-Equity ranked higher than
70.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ARNA: 0.04
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.58, Max: 19.85
Current: 0.04
0
19.85
Debt-to-EBITDA 0.08
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ARNA: 0.08
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -82.2, Med: -1.12, Max: 0.08
Current: 0.08
-82.2
0.08
Interest Coverage 114.32
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ARNA: 114.32
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.13, Med: 0.13, Max: 114.32
Current: 114.32
0.13
114.32
Piotroski F-Score 8
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 20.78
DISTRESS
GREY
SAFE
Beneish M-Score 35.77
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 657.56%
WACC 11.05%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 76.41
Operating Margin ranked lower than
72.47% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ARNA: 76.41
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1300.31, Med: -477.45, Max: 76.41
Current: 76.41
-1300.31
76.41
Net Margin % 76.19
Net Margin ranked lower than
74.37% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ARNA: 76.19
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1474.96, Med: -369.13, Max: 76.19
Current: 76.19
-1474.96
76.19
ROE % 88.35
ROE ranked higher than
55.41% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ARNA: 88.35
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -246.16, Med: -123.18, Max: 88.35
Current: 88.35
-246.16
88.35
ROA % 78.82
ROA ranked higher than
58.49% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ARNA: 78.82
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -64.15, Med: -38.24, Max: 78.82
Current: 78.82
-64.15
78.82
ROC (Joel Greenblatt) % 2367.64
ROC (Joel Greenblatt) ranked higher than
56.66% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ARNA: 2367.64
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -500.1, Med: -109.69, Max: 2367.64
Current: 2367.64
-500.1
2367.64
3-Year Total Revenue Growth Rate 10.30
3-Year Revenue Growth Rate ranked lower than
72.81% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ARNA: -11.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate -9.50
3-Year EBITDA Growth Rate ranked lower than
64.46% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ARNA: 12.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -74.3, Med: 10, Max: 70.7
Current: 12.4
-74.3
70.7
3-Year EPS w/o NRI Growth Rate 49.00
3-Year EPS w/o NRI Growth Rate ranked lower than
56.88% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ARNA: 49
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -104.7, Med: 16.7, Max: 57.1
Current: 49
-104.7
57.1

» ARNA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ARNA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XSWX:GALE NAS:AKCA NAS:DNLI SZSE:300009 NAS:HALO NAS:INSM NAS:RETA OSTO:VITR NAS:PTCT NAS:PTLA NAS:MRTX NAS:LGND SZSE:002603 NAS:XLRN XSWX:IDIA NAS:QURE NAS:CRSP TSE:4974 NAS:ANAB NAS:ICPT
Traded in other countries RN3N.Germany 0S54.UK
Address 6154 Nancy Ridge Drive, San Diego, CA, USA, 92121
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Ratios

Current vs industry vs history
PE Ratio (TTM) 4.40
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ARNA: 4.4
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 3.57, Med: 3.9, Max: 4.54
Current: 4.4
3.57
4.54
Forward PE Ratio 5.49
Forward P/E ranked lower than
100.00% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
ARNA: 5.49
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 4.40
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ARNA: 4.4
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 3.57, Med: 3.9, Max: 4.54
Current: 4.4
3.57
4.54
Price-to-Owner-Earnings 3.78
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
ARNA: 3.78
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 3.07, Med: 57.55, Max: 330.66
Current: 3.78
3.07
330.66
PB Ratio 2.21
PB Ratio ranked higher than
58.32% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ARNA: 2.21
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.23, Med: 7.73, Max: 135.77
Current: 2.21
1.23
135.77
PS Ratio 3.32
PS Ratio ranked lower than
85.26% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ARNA: 3.32
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.71, Med: 26.27, Max: 135.13
Current: 3.32
2.71
135.13
Price-to-Free-Cash-Flow 4.35
Price-to-Free-Cash-Flow ranked lower than
100.00% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ARNA: 4.35
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 3.52, Med: 24.19, Max: 183.33
Current: 4.35
3.52
183.33
Price-to-Operating-Cash-Flow 4.33
Price-to-Operating-Cash-Flow ranked lower than
100.00% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ARNA: 4.33
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 3.51, Med: 20.88, Max: 129.9
Current: 4.33
3.51
129.9
EV-to-EBIT 2.56
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ARNA: 2.56
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -187.7, Med: -7.65, Max: 2.7
Current: 2.56
-187.7
2.7
EV-to-EBITDA 2.54
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ARNA: 2.54
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -350.4, Med: -4.8, Max: 722.4
Current: 2.54
-350.4
722.4
EV-to-Revenue 1.97
EV-to-Revenue ranked lower than
79.38% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ARNA: 1.97
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.4, Med: 23.4, Max: 116.4
Current: 1.97
1.4
116.4
Current Ratio 35.51
Current Ratio ranked higher than
95.72% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ARNA: 35.51
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.68, Med: 6.85, Max: 91.72
Current: 35.51
1.68
91.72
Quick Ratio 35.51
Quick Ratio ranked higher than
95.72% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ARNA: 35.51
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.68, Med: 6.84, Max: 91.72
Current: 35.51
1.68
91.72
Days Sales Outstanding 1.38
Days Sales Outstanding ranked higher than
53.89% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ARNA: 1.38
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 1.38, Med: 48.63, Max: 134.42
Current: 1.38
1.38
134.42
Days Payable 136.29
Days Payable ranked higher than
54.66% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ARNA: 136.29
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 30.81, Med: 120.14, Max: 386.18
Current: 136.29
30.81
386.18

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -24.60
3-Year Share Buyback Rate ranked lower than
64.06% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ARNA: -24.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -205.3, Med: -21.5, Max: 1.2
Current: -24.6
-205.3
1.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.20
Price-to-Tangible-Book ranked higher than
66.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ARNA: 2.2
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.62, Med: 3.27, Max: 70.08
Current: 2.2
0.62
70.08
Price-to-Projected-FCF 1.76
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
100.00% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
ARNA: 1.76
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.48, Med: 1.48, Max: 1.83
Current: 1.76
1.48
1.83
Price-to-Median-PS-Value 0.13
Price-to-Median-PS-Value ranked lower than
91.89% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ARNA: 0.13
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.11, Med: 0.8, Max: 5.88
Current: 0.13
0.11
5.88
Price-to-Graham-Number 0.66
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
ARNA: 0.66
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.55, Med: 0.55, Max: 0.68
Current: 0.66
0.55
0.68
Earnings Yield (Joel Greenblatt) % 39.47
Earnings Yield (Greenblatt) ranked lower than
51.25% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ARNA: 39.47
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -149.2, Med: -10.45, Max: 54
Current: 39.47
-149.2
54

More Statistics

Revenue (TTM) (Mil) $ 817.27
EPS (TTM) $ 12.1
Beta 1.46
Volatility % 45.89
52-Week Range $ 31.97 - 58
Shares Outstanding (Mil) 49.57

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 8
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y